Celldex Therapeutics Stock
Price
Target price
?
?
3.180%
0.9
3.180%
€38.19
08:14 / Frankfurt
WKN: A2PEAB / Symbol: CLDX / Name: Celldex / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Celldex Therapeutics Stock
Celldex Therapeutics dominated the market today, gaining €0.90 (3.180%).
Currently there is a rather positive sentiment for Celldex Therapeutics with 9 Buy predictions and 3 Sell predictions.
As a result the target price of 38 € shows a positive potential of 30.05% compared to the current price of 29.22 € for Celldex Therapeutics.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Celldex Therapeutics stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Celldex Therapeutics in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
B****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Celldex Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Celldex Therapeutics | 3.180% | -0.106% | 10.625% | 80.382% | 28.727% | -3.673% | 42.670% |
| Larimar Therapeutics Inc. | -1.490% | -1.463% | 9.783% | 143.373% | 21.687% | -3.349% | -57.021% |
| Northwest Biotherapeutics Inc. | -10.000% | 12.500% | -14.286% | -47.977% | -12.621% | -66.355% | -83.019% |
| Achieve Life Sciences Inc. | -0.470% | 53.571% | 15.282% | 134.716% | 16.216% | -39.007% | -49.112% |
Comments
Celldex Therapeutics (CLDX) was upgraded by Barclays PLC from "underweight" to "overweight". They now have a $45.00 price target on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) was upgraded by Wolfe Research from "peer perform" to "outperform". They now have a $44.00 price target on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) had its "buy" rating reaffirmed by Stifel Nicolaus. They now have a $68.00 price target on the stock, up from $58.00.
Show more
Ratings data for CLDX provided by MarketBeat
News
Celldex Therapeutics SVPs Engage In Heavy Transactions
On Dec. 4, 2025, Freddy A. Jimenez, Senior Vice President & General Counsel of Celldex Therapeutics (NASDAQ:CLDX), executed an open-market sale of 4,166 insider shares. See SEC Form 4 filing.
